title: Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy.
abstract: The rapid growth of hepatocellular carcinoma (HCC) leading to tumor hypoxia is a common pathological phenomenon. Meanwhile, tumor hypoxia can promote a change in the biological properties of tumor cells. It may enhance the survival of tumor cells under stress conditions, resulting in resistance to apoptosis and angiogenesis. The moleculars that could modulate the malignant phenotypes of HCC cells remain largely unknown. Based on label-free quantitative proteomic data, we found a significant upregulation of prohibitin-2 (PHB2) in HCC tissues. Treatment of hepatoma cells with small interfering RNAs against PHB2 suppressed cell growth and colony formation, led to G1 phase arrest and sensitized HCC cells to apoptosis. Moreover, inhibition of PHB2 expression dramatically repressed the ability of HCC cells to adapt to hypoxic microenvironments and resist chemotherapy-induced apoptosis. Thus, PHB2 in HCC supports the development and progression of hepatocellular malignancy to hypoxia, and implicates the potential antagonist function of PHB2 in transarterial chemoembolization treatment.
authors: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R., China; Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Zhejiang University, Hangzhou, P.R., China.
authors: Jun
authors: J
authors: Cheng
authors: Feng
authors: F
authors: Gao
authors: Xiang
authors: X
authors: Chen
authors: Jian
authors: J
authors: Wu
authors: Chunyang
authors: C
authors: Xing
authors: Zhen
authors: Z
authors: Lv
authors: Wei
authors: W
authors: Xu
authors: Qing
authors: Q
authors: Xie
authors: Liming
authors: L
authors: Wu
authors: Sunyi
authors: S
authors: Ye
authors: Haiyang
authors: H
authors: Xie
authors: Shusen
authors: S
authors: Zheng
authors: Lin
authors: L
authors: Zhou
mesh_terms: D000595:Amino Acid Sequence; D017209:Apoptosis; D063646:Carcinogenesis / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology; D015687:Cell Hypoxia; D002465:Cell Movement; D049109:Cell Proliferation; D059585:G1 Phase Cell Cycle Checkpoints; D055785:Gene Knockdown Techniques; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology; D008969:Molecular Sequence Data; D000091402:Prohibitins; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics; D012097:Repressor Proteins / Q000502:physiology*; D059467:Transcriptome
chemical_list: C000717331:PHB2 protein, human; D000091402:Prohibitins; D020543:Proteome; D012097:Repressor Proteins
keywords: biomarker; hepatocellular carcinoma; label-free; prohibitin-2; proteomics